Reversal of trauma-induced amnesia in mice by a thrombin receptor antagonist

Zeev Itzekson1, Nicola Maggio, Anat Milman

  • 1Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

Insights

Minimal traumatic brain injury (mTBI) causes amnesia by activating thrombin, which acts via protease-activated receptor 1 (PAR-1). Blocking PAR-1 prevents these memory deficits, offering a new therapeutic target for brain trauma.

Area of Science:

  • Neuroscience
  • Traumatic Brain Injury Research
  • Coagulation Factor Research

Background:

  • Minimal traumatic brain injury (mTBI) is linked to memory loss and bleeding.
  • Activated coagulation factors, particularly thrombin, are implicated in mTBI-related amnesia.

Purpose of the Study:

  • To investigate the role of thrombin and its receptor PAR-1 in mTBI-induced amnesia.
  • To explore PAR-1 as a potential therapeutic target for cognitive deficits following brain trauma.

Main Methods:

  • Assessed amnesia using the novel object recognition test in an mTBI model.
  • Measured thrombin activity and long-term potentiation (LTP) in hippocampal slices.
  • Utilized PAR-1 agonists and antagonists (SCH79797) in intracerebroventricular injections.

Main Results:

  • Thrombin activity increased significantly post-mTBI.
  • mTBI, thrombin, and PAR-1 agonist induced amnesia, impairing object recognition.
  • PAR-1 antagonist SCH79797 completely blocked amnesia and restored LTP.
  • LTP was impaired by mTBI and thrombin, but reversed by the antagonist.

Conclusions:

  • Thrombin signaling through PAR-1 plays a critical role in mTBI-induced amnesia.
  • Targeting PAR-1 presents a novel therapeutic strategy for cognitive impairments after brain injury.

Related Concept Videos